AZD-1222/immune-globulin/tozinameran

LAMENESS SURVEY IN Y AZD PROVINCE IN 1992-1993

Imaging colon cancer response following treatment with AZD 1152 : a preclinical

Authors Affiliations: Departments of Neurology and Radiology, Sloan Kettering Institute Molecular Pharmacology and Chemistry Program.Cyclotron and Radiochemistry Core Facility, Department of Medicine, Laboratory of New Drug Development. Memorial Sloan-Kettering Cancer Center, New York, New York. 6 Departments of Medicine and Pharmacology, CINJ, RWJMS, UMDNJ, NJ Research funding: AstraZeneca and...

Clinical pharmacokinetics of AZD 3199 , an inhaled ultra - long - acting 2 - adrenoreceptor agonist

LMP - 400 by the cell checkpoint and Chk 1 - Chk 2 inhibitor , AZD 7762

Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. Abstract Novel topoisomerase I (Top1) inhibitors are in clinical development to circumvent the drawbacks of camptothecins. Here we report molecular investigations into LMP-400, an indenoisoquinoline Top1 inhibitor in Phase 1 clinical trial, by itself and in combination with the cell cycle check...

Antitumor activity of Src inhibitor saracatinib (AZD-0530) in preclinical models of biliary tract carcinomas.

Biliary tract carcinoma (BTC) has a poor prognosis due to limited treatment options. There is, therefore, an urgent need to identify new targets and to design innovative therapeutic approaches. Among potential candidate molecules, we evaluated the nonreceptor tyrosine kinase Src, observing promising antitumor effects of its small-molecule inhibitor saracatinib in BTC preclinical models. The pre...